987 related articles for article (PubMed ID: 27521738)
1. Therapeutic Approach to Adult Fibrotic Lung Diseases.
Adegunsoye A; Strek ME
Chest; 2016 Dec; 150(6):1371-1386. PubMed ID: 27521738
[TBL] [Abstract][Full Text] [Related]
2. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
[TBL] [Abstract][Full Text] [Related]
3. Interstitial Lung Disease: A Review.
Maher TM
JAMA; 2024 May; 331(19):1655-1665. PubMed ID: 38648021
[TBL] [Abstract][Full Text] [Related]
4. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
5. The evolving pharmacotherapy of pulmonary fibrosis.
Lota HK; Wells AU
Expert Opin Pharmacother; 2013 Jan; 14(1):79-89. PubMed ID: 23265249
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
7. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
[TBL] [Abstract][Full Text] [Related]
8. Update in diffuse parenchymal lung disease, 2013.
Rosas IO; Kaminski N
Am J Respir Crit Care Med; 2015 Feb; 191(3):270-4. PubMed ID: 25635490
[TBL] [Abstract][Full Text] [Related]
9. [Antifibrotic therapy - new approvals for non-IPF interstitial lung diseases].
Markart P; Drakopanagiotakis F; Wygrecka M
Dtsch Med Wochenschr; 2021 Feb; 146(3):181-184. PubMed ID: 33513653
[TBL] [Abstract][Full Text] [Related]
10. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
Makino S
Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
[TBL] [Abstract][Full Text] [Related]
11. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?
de Lauretis A; Veeraraghavan S; Renzoni E
Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375
[TBL] [Abstract][Full Text] [Related]
12. Evaluating new treatment options.
Nathan SD
Am J Manag Care; 2017 Jul; 23(11 Suppl):S183-S190. PubMed ID: 28978213
[TBL] [Abstract][Full Text] [Related]
13. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
George PM; Wells AU
Expert Rev Clin Pharmacol; 2017 May; 10(5):483-491. PubMed ID: 28266906
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic targets in idiopathic pulmonary fibrosis.
Kolb M; Bonella F; Wollin L
Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
[TBL] [Abstract][Full Text] [Related]
15. Current approaches to the management of idiopathic pulmonary fibrosis.
Raghu G; Richeldi L
Respir Med; 2017 Aug; 129():24-30. PubMed ID: 28732832
[TBL] [Abstract][Full Text] [Related]
16. Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial.
Behr J; Neuser P; Prasse A; Kreuter M; Rabe K; Schade-Brittinger C; Wagner J; Günther A
BMC Pulm Med; 2017 Sep; 17(1):122. PubMed ID: 28877715
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
18. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.
Jo HE; Troy LK; Keir G; Chambers DC; Holland A; Goh N; Wilsher M; de Boer S; Moodley Y; Grainge C; Whitford H; Chapman S; Reynolds PN; Glaspole I; Beatson D; Jones L; Hopkins P; Corte TJ
Respirology; 2017 Oct; 22(7):1436-1458. PubMed ID: 28845557
[TBL] [Abstract][Full Text] [Related]
19. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
20. Developments in the management of idiopathic pulmonary fibrosis.
Drug Ther Bull; 2015 Jul; 53(7):78-81. PubMed ID: 26159700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
